The estimated Net Worth of Marco Taglietti is at least $1.37 Million dollars as of 26 April 2022. Dr Taglietti owns over 75,000 units of Scynexis Inc stock worth over $380,895 and over the last 10 years he sold SCYX stock worth over $0. In addition, he makes $991,270 as CEO and Pres & Director at Scynexis Inc.
Dr has made over 28 trades of the Scynexis Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 75,000 units of SCYX stock worth $225,000 on 26 April 2022.
The largest trade he's ever made was buying 200,000 units of Scynexis Inc stock on 27 July 2015 worth over $106,000. On average, Dr trades about 24,008 units every 48 days since 2014. As of 26 April 2022 he still owns at least 272,068 units of Scynexis Inc stock.
You can see the complete history of Dr Taglietti stock trades at the bottom of the page.
Dr. Marco Taglietti is the CEO, Pres & Director at Scynexis Inc.
As the CEO and Pres & Director of Scynexis Inc, the total compensation of Dr Taglietti at Scynexis Inc is $991,270. There are no executives at Scynexis Inc getting paid more.
Dr Taglietti is 60, he's been the CEO and Pres & Director of Scynexis Inc since . There are 7 older and 7 younger executives at Scynexis Inc. The oldest executive at Scynexis Inc is Patrick Langlois, 70, who is the Director.
Marco's mailing address filed with the SEC is C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN, NJ, 07059.
Over the last 11 years, insiders at Scynexis Inc have traded over $4,708,140 worth of Scynexis Inc stock and bought 2,173,590 units worth $13,469,713 . The most active insiders traders include Advisors Llcperceptive Life..., Patrick Machado, and Marco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of $64,694. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth $225,000.
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
Scynexis Inc executives and other stock owners filed with the SEC include: